SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000899140-22-000118
Filing Date
2022-02-02
Accepted
2022-02-01 18:34:16
Documents
3
Group Members
INNOVIVA STRATEGIC OPPORTUNITIES LLC

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D/A, #6 i50424071a.htm SC 13D/A 39457
2 PROPOSAL TO MEMBERS OF BOARD OF DIRECTORS OF THE ISSUER i50414071b.htm EX-11 7035
3 image0.jpg GRAPHIC 33539
  Complete submission text file 0000899140-22-000118.txt   94534
Mailing Address 1350 OLD BAYSHORE HIGHWAY SUITE 400 BURLINGAME CA 94010
Business Address 1350 OLD BAYSHORE HIGHWAY SUITE 400 BURLINGAME CA 94010 6502389600
Innoviva, Inc. (Filed by) CIK: 0001080014 (see all company filings)

IRS No.: 943265960 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A
SIC: 2834 Pharmaceutical Preparations

Mailing Address 35 GATEHOUSE DRIVE WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE WALTHAM MA 02451 (781) 810-0120
Entasis Therapeutics Holdings Inc. (Subject) CIK: 0001724344 (see all company filings)

IRS No.: 824592913 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-90651 | Film No.: 22580659
SIC: 2834 Pharmaceutical Preparations